IONIS PHARMACEUTICALS INC (IONS)

Five stocks we like better than Ionis Pharmaceuticals · Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector · Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case

The average weekly price growth across all stocks in the @Biotechnology industry was -1.97%. For the same industry, the average monthly price growth was -7.35%, and the average quarterly price growth was +2126.94%. IONS is expected to report earnings on Nov 04, 2026.

Ionis Pharmaceuticals stock slipped about 1.4% today and sits near US$53 after a tough few months that left shares down roughly one third over 30 and 90 days. The price reaction looks modest next to the earnings headline.

Ionis Pharmaceuticals IONS reported second-quarter 2026 adjusted loss per share of 43 cents, narrower than the Zacks Consensus Estimate of a loss of 89 cents. In the year-ago period, the company had posted adjusted earnings of 86 cents.The adjusted earnings/loss exclude compensation expenses ...

Ionis also exceeded revenue expectations, posting $268 million compared to the forecasted $190.06 million. This positive performance was attributed to increased sales of new medicines and ongoing collaboration income. Despite these results, investors appeared to weigh the earnings beat against ...